NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis $52.62 -1.68 (-3.09%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.66 +0.04 (+0.07%) As of 09/12/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get MLTX alerts:Sign Up Key Stats Today's Range$52.45▼$54.9750-Day Range$46.75▼$61.1252-Week Range$31.42▼$61.87Volume864,952 shsAverage Volume575,855 shsMarket Capitalization$3.38 billionP/E RatioN/ADividend YieldN/APrice Target$74.43Consensus RatingModerate Buy Company Overview MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates. Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis. Early studies have shown promising results in enhancing immune regulation and diminishing muscle inflammation. MoonLake is conducting ongoing clinical trials to assess the safety, tolerability, and efficacy of MLTX101, while also advancing additional preclinical programs for other autoimmune and inflammatory indications. Headquartered in the United States, MoonLake Immunotherapeutics collaborates with academic institutions, contract research organizations and industry partners to accelerate its research pipeline. The leadership team brings extensive expertise in immunology, drug development and regulatory affairs, guiding the company’s efforts to translate scientific innovation into patient-focused therapies. As a NASDAQ-listed company under the ticker MLTX, MoonLake continues to build strategic collaborations to support the growth of its clinical programs and expand its global reach.AI Generated. May Contain Errors. Read More MoonLake Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreMLTX MarketRank™: MoonLake Immunotherapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 621st out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialMoonLake Immunotherapeutics has a consensus price target of $74.43, representing about 41.4% upside from its current price of $52.62.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 3 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.79) to ($2.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -18.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -18.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 7.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MoonLake Immunotherapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.39% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.39% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 10.2, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently decreased by 3.54%, indicating that investor sentiment is improving. News and Social Media3.5 / 5News Sentiment1.28 News SentimentMoonLake Immunotherapeutics has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for MoonLake Immunotherapeutics this week, compared to 5 articles on an average week.Search Interest11 people have searched for MLTX on MarketBeat in the last 30 days. This is an increase of 450% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -64% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MLTX Stock News HeadlinesLeerink Partners Reiterated a Buy on MoonLake Immunotherapeutics (MLTX)September 10 at 3:11 AM | insidermonkey.comCantor Fitzgerald Has Weak Outlook for MLTX FY2025 EarningsSeptember 6, 2025 | americanbankingnews.comREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today. | Paradigm Press (Ad)2 Small-Cap Biotech Stocks Well Positioned for a BreakoutAugust 27, 2025 | fool.comLeerink Partners Keeps Their Buy Rating on MoonLake Immunotherapeutics (MLTX)August 22, 2025 | theglobeandmail.comClear Street Sticks to Their Buy Rating for MoonLake Immunotherapeutics (MLTX)August 22, 2025 | theglobeandmail.comBuy Rating for MoonLake Immunotherapeutics: Anticipated Success of Sonelokimab in Phase 3 VELA TrialAugust 22, 2025 | tipranks.comMoonLake Immunotherapeutics (MLTX): A Bull Case TheoryAugust 16, 2025 | insidermonkey.comSee More Headlines MLTX Stock Analysis - Frequently Asked Questions How have MLTX shares performed this year? MoonLake Immunotherapeutics' stock was trading at $54.15 at the start of the year. Since then, MLTX stock has decreased by 2.8% and is now trading at $52.62. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) issued its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by $0.14. Who are MoonLake Immunotherapeutics' major shareholders? Top institutional shareholders of MoonLake Immunotherapeutics include Westfield Capital Management Co. LP (1.97%), Federated Hermes Inc. (1.95%), Alliancebernstein L.P. (1.78%) and Hood River Capital Management LLC (1.06%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Matthias Bodenstedt, Simon Sturge and Kristian Reich. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MoonLake Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MoonLake Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Disc Medicine (IRON), e.l.f. Beauty (ELF), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Arista Networks (ANET). Company Calendar Last Earnings8/05/2025Today9/13/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLTX CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Price Target for MoonLake Immunotherapeutics$74.43 High Price Target$100.00 Low Price Target$61.00 Potential Upside/Downside+41.4%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($2.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$118.94 million Net MarginsN/A Pretax MarginN/A Return on Equity-40.98% Return on Assets-35.81% Debt Debt-to-Equity Ratio0.21 Current Ratio16.65 Quick Ratio16.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.09 per share Price / Book7.42Miscellaneous Outstanding Shares64,230,000Free Float56,510,000Market Cap$3.38 billion OptionableOptionable Beta1.27 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:MLTX) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.